Literature DB >> 18715733

In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.

Cristina Seral1, Laura Suárez, Carmen Rubio-Calvo, Rafael Gómez-Lus, Mercedes Gimeno, Pilar Coronel, Estrella Durán, Raquel Becerril, Mercedes Oca, F Javier Castillo.   

Abstract

In vitro cefditoren antimicrobial activity was tested against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in our hospital from January 2005 to May 2006 by agar dilution and broth microdilution method, respectively. MICs were also determined for 13 and 10 comparison drugs, respectively. The pneumococci tested comprised 113 (39.2%) penicillin susceptible, 91 (31.6%) penicillin intermediate, and 84 (29.2%) penicillin resistant. Cefditoren was the most active drug on the basis of the MICs (MIC(90)=0.5 microg/mL), followed by ceftriaxone and levofloxacin (MIC(90)=1 microg/mL). Cefditoren MICs ranged from 0.25 to 1 microg/mL for ceftriaxone-resistant isolates, with a modal MIC of 0.5 microg/mL and an MIC(90) of 1.0 microg/mL. No S. pneumoniae isolates evaluated in this study showed MICs to cefditoren higher than 1 microg/mL (MIC range, <or=0.015 to 1 microg/mL). Against penicillin-resistant pneumococci, the rank order of intrinsic activity (MIC(90), microg/mL) was cefditoren (0.5)<ceftriaxone (2.0)=cefotaxime (2.0)<amoxicillin/clavulanate (8.0)=amoxicillin (8.0)=cefuroxime (8.0). Among the 220 strains of H. influenzae, 42 (19.09%) produced a beta-lactamase (Hi beta+) and 3 (1.1%) were beta-lactamase (Hi beta-) negative but have reduced susceptibility to ampicillin (BLNAR). The most active drugs on the basis of MICs were cefditoren and levofloxacin, showing MIC(50) and MIC(90) values of 0.015/0.06 microg/mL. Cefditoren at concentration of 0.06 microg/mL inhibited all 3 BLNAR (ampicillin MICs >4 microg/mL). Against H. influenzae (Hi beta+), the rank order of intrinsic activity (MIC(90), microg/mL) was cefditoren (0.03) < cefixime (0.06)<ceftriaxone (0.12)=cefotaxime (0.12)<cefuroxime (1.0)<amoxicillin/clavulanate (2.0)<ampicillin (>8.0).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18715733     DOI: 10.1016/j.diagmicrobio.2008.06.007

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  4 in total

1.  Update on the clinical utility and optimal use of cefditoren.

Authors:  José Barberán; Lorenzo Aguilar; María-José Giménez
Journal:  Int J Gen Med       Date:  2012-05-21

2.  A Comparison of Cefditoren Pivoxil 8-12 mg/kg/day and Cefditoren Pivoxil 16-20 mg/kg/day in Treatment of Children With Acute Presumed Bacterial Rhinosinusitis: A Prospective, Randomized, Investigator-Blinded, Parallel-Group Study.

Authors:  Orapan Poachanukoon; Auchara Tangsathapornpong; Sermkiat Tanuchit
Journal:  Clin Exp Otorhinolaryngol       Date:  2015-05-13       Impact factor: 3.372

Review 3.  Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults.

Authors:  María-José Giménez; Lorenzo Aguilar; Juan José Granizo
Journal:  Multidiscip Respir Med       Date:  2018-11-02

Review 4.  From Evidence to Clinical Guidelines in Antibiotic Treatment in Acute Otitis Media in Children.

Authors:  Elena Lia Spoială; Gabriela Dumitrita Stanciu; Veronica Bild; Daniela Carmen Ababei; Cristina Gavrilovici
Journal:  Antibiotics (Basel)       Date:  2021-01-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.